

**WHAT IS CLAIMED IS:**

1. An expression enhancer for protein synthesis inhibitory genes, said expression enhancer comprising IFN- $\alpha$ 2 and IFN- $\alpha$ 8 subtypes of human IFN- $\alpha$  as active ingredients.

2. The expression enhancer according to claim 1, wherein at least 90% of the total human IFN- $\alpha$  activity as expressed in international units is of the IFN- $\alpha$ 2 and IFN- $\alpha$ 8 subtypes.

3. The expression enhancer according to claim 1 wherein the activity ratio, in terms of international units, of the IFN- $\alpha$ 2 and IFN- $\alpha$ 8 subtypes is at least 1:0.25 but below 1:1.5.

4. The expression enhancer according to claim 2 wherein the activity ratio, in terms of international units, of the IFN- $\alpha$ 2 and IFN- $\alpha$ 8 subtypes is at least 1:0.25 but below 1:1.5.

5. The expression enhancer according to claim 1 which is for a member of the group consisting of 2',5'-oligoadenylate synthetase gene, double-stranded RNA-dependent protein kinase gene, and mixtures thereof, as a protein synthesis inhibitory gene.

6. The expression enhancer according to claim 2 which is for a member of the group consisting of 2',5'-oligoadenylate synthetase gene, double-stranded RNA-dependent protein kinase gene, and mixtures thereof, as a protein synthesis inhibitory gene.

7. The expression enhancer according to claim 3 which is for a member of the group consisting of 2',5'-oligoadenylate synthetase gene, double-stranded RNA-dependent protein kinase gene, and mixtures thereof, as a protein synthesis inhibitory gene.

8. An expression enhancer for protein synthesis inhibitory genes comprising IFN- $\alpha$ 2 and IFN- $\alpha$ 8 subtypes of human IFN- $\alpha$  as active ingredients, in a weight ratio of 1:0.05 to 1:0.5.

9. The expression enhancer according to claim 1 wherein the IFN- $\alpha$ 2 and IFN- $\alpha$ 8 subtypes have a water-soluble macromolecule covalently coupled to the peptide chains of the subtypes.

10. The expression enhancer according to claim 5 wherein the IFN- $\alpha$ 2 and IFN- $\alpha$ 8 subtypes have a water-soluble macromolecule covalently coupled to the peptide chains of the subtypes.

11. The expression enhancer according to claim 10 wherein the water-soluble macromolecule is a polysaccharide consisting essentially of a repeating unit of maltotriose.

12. An expression enhancer for genes comprising IFN- $\alpha$ 2 and IFN- $\alpha$ 8 subtypes of human IFN- $\alpha$  as active ingredients for use as an expression enhancer for structure genes under the regulation of a transcription regulatory region selected from the group consisting of 2',5'-oligoadenylate synthetase gene, double-stranded RNA-dependent protein kinase gene, and mixtures thereof.

13. A pharmaceutical composition comprising an expression enhancer according to claim 1 as an active ingredient and a pharmaceutically acceptable excipient.

14. A pharmaceutical composition comprising an expression enhancer according to claim 5 as an active ingredient and at least one member of the group consisting of pharmaceutically acceptable excipients, carriers, buffers, and stabilizers.

15. An enhancer for gene expression inducing action of protein synthesis inhibitory genes by IFN- $\alpha$ 8 subtype of human IFN- $\alpha$ , comprising IFN- $\alpha$ 2 subtype of human IFN- $\alpha$  as an active ingredient.

16. An enhancer for gene expression inducing action of protein synthesis inhibitory genes by IFN- $\alpha$ 2 subtype of human IFN- $\alpha$ , comprising IFN- $\alpha$ 8 subtype of human IFN- $\alpha$  as an active ingredient.

17. The enhancer according to claim 15 wherein said protein synthesis inhibitory gene is selected from the group consisting of 2',5'-oligoadenylate synthetase gene, double-stranded RNA-dependent protein kinase gene, and mixtures thereof.

18. The enhancer according to claim 16 wherein said protein synthesis inhibitory gene is selected from the group consisting of 2',5'-oligoadenylate synthetase gene, stranded-stranded RNA-dependent protein kinase gene, and mixtures thereof.